Lexaria Bioscience receives FDA clearance for Phase 1b hypertension trial HYPER-H23-1

Lexaria Bioscience Corp.

FDA issued 'Study May Proceed' letter on Feb 29, 2024, for Lexaria's Investigational New Drug application.
Trial HYPER-H23-1 is a randomized, double-blind, placebo-controlled study of DehydraTECH-CBD in Stage 1 or Stage 2 hypertension.
Clinical trial commencement is contingent on Lexaria raising sufficient funding.
FDA review completion marks a key milestone for Lexaria's DehydraTECH-CBD program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.